JP2022504182A5 - - Google Patents

Info

Publication number
JP2022504182A5
JP2022504182A5 JP2021518473A JP2021518473A JP2022504182A5 JP 2022504182 A5 JP2022504182 A5 JP 2022504182A5 JP 2021518473 A JP2021518473 A JP 2021518473A JP 2021518473 A JP2021518473 A JP 2021518473A JP 2022504182 A5 JP2022504182 A5 JP 2022504182A5
Authority
JP
Japan
Prior art keywords
dosage form
oral dosage
cav3 antagonist
plasma concentration
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518473A
Other languages
English (en)
Japanese (ja)
Other versions
JP7480131B2 (ja
JP2022504182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/054498 external-priority patent/WO2020072773A1/en
Publication of JP2022504182A publication Critical patent/JP2022504182A/ja
Publication of JP2022504182A5 publication Critical patent/JP2022504182A5/ja
Priority to JP2024070307A priority Critical patent/JP7855629B2/ja
Application granted granted Critical
Publication of JP7480131B2 publication Critical patent/JP7480131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518473A 2018-10-03 2019-10-03 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 Active JP7480131B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070307A JP7855629B2 (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862740755P 2018-10-03 2018-10-03
US62/740,755 2018-10-03
US201862780049P 2018-12-14 2018-12-14
US62/780,049 2018-12-14
PCT/US2019/054498 WO2020072773A1 (en) 2018-10-03 2019-10-03 Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070307A Division JP7855629B2 (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Publications (3)

Publication Number Publication Date
JP2022504182A JP2022504182A (ja) 2022-01-13
JP2022504182A5 true JP2022504182A5 (enExample) 2022-10-12
JP7480131B2 JP7480131B2 (ja) 2024-05-09

Family

ID=70055875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518473A Active JP7480131B2 (ja) 2018-10-03 2019-10-03 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
JP2024070307A Active JP7855629B2 (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070307A Active JP7855629B2 (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Country Status (12)

Country Link
US (3) US12383539B2 (enExample)
EP (1) EP3860571A4 (enExample)
JP (2) JP7480131B2 (enExample)
KR (1) KR102946985B1 (enExample)
CN (1) CN113164393A (enExample)
AU (2) AU2019355021B2 (enExample)
BR (1) BR112021006398A2 (enExample)
CA (1) CA3115235A1 (enExample)
IL (2) IL300798B2 (enExample)
MX (2) MX2021003706A (enExample)
TW (2) TW202602439A (enExample)
WO (1) WO2020072773A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
KR102654466B1 (ko) 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
TW202602439A (zh) 2018-10-03 2026-01-16 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
TWI870475B (zh) * 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料
EP4142764A4 (en) * 2020-04-29 2024-05-29 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators
US20240238261A1 (en) * 2021-05-24 2024-07-18 Cavion, Inc. Method of treating essential tremor
AU2024229800A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Methods of treating essential tremor
KR20250165616A (ko) * 2023-03-02 2025-11-26 프락시스 프리시젼 메디신즈, 인크. 고함량 단일 투여 단위 제형 및 이의 사용 방법

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389752C (zh) * 1978-04-21 2008-05-28 莱博法姆公司 控释组合物
CA1319144C (en) 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
KR19990082476A (ko) 1996-02-14 1999-11-25 하우스 한스 루돌프, 긴터 베아트리체 당-변형되어 갭이 형성된 올리고뉴클레오티드
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
AU2002303295B2 (en) 2001-04-06 2006-11-30 Univ New York Diagnosis and treatment of neural disease and injury using microvoltammetry
EP1465995B1 (en) 2002-01-17 2008-07-30 The University of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
CA2486551C (en) 2002-07-01 2012-01-03 University Of Manitoba A sensor system and method for measuring strain in structure
WO2004035000A2 (en) 2002-10-17 2004-04-29 Merck & Co., Inc. Enhancement of sleep with t-type calcium channel antagonists
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1492519B1 (en) 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using antimuscarinics and alpha-2-delta subunit calcium channel modulators
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
AU2005277154B2 (en) 2004-08-20 2011-11-24 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
AU2005277156B2 (en) 2004-08-20 2011-12-01 University Of Virginia Patent Foundation T type calcium channel inhibitors
US7745452B2 (en) 2005-03-09 2010-06-29 Merck Sharp & Dohme Corp. Quinazolinone T-type calcium channel antagonists
US20100222387A1 (en) 2005-06-23 2010-09-02 Barrow James C 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
CN101212974A (zh) 2005-06-29 2008-07-02 默克公司 4-氟-哌啶t-型钙通道拮抗剂
WO2007007852A1 (ja) 2005-07-14 2007-01-18 Teijin Chemicals Ltd. 発泡樹脂シートおよび液晶表示装置
KR100654328B1 (ko) 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
EP1968956A2 (en) 2005-12-22 2008-09-17 Icagen, Inc. Calcium channel antagonists
ES2566481T3 (es) 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
KR100749843B1 (ko) 2006-07-13 2007-08-21 한국과학기술연구원 Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법
KR100969686B1 (ko) 2006-08-07 2010-07-14 한국과학기술연구원 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
JP2010503673A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
JP2010503676A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CA2663503A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
CN101686952A (zh) 2007-03-12 2010-03-31 Vm生物医药公司 新型钙离子通道调节剂
WO2008117148A1 (en) 2007-03-23 2008-10-02 Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
US20100210671A1 (en) 2007-07-10 2010-08-19 Barrow James C Quinazolinone T-Type Calcium Channel Antagonists
KR101079459B1 (ko) 2007-09-14 2011-11-03 이화여자대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물
CA2701594C (en) 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Heterocycle phenyl amide t-type calcium channel antagonists
US20100249176A1 (en) 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
WO2009054982A1 (en) 2007-10-24 2009-04-30 Merck & Co., Inc. Pyrazinyl amide t-type calcium channel antagonists
WO2009056934A1 (en) 2007-10-31 2009-05-07 Pfizer Products Inc. 1,4-dihydronaphthyridine derivatives
KR100917037B1 (ko) 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
WO2009132454A1 (en) 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
CN102065858B (zh) 2008-04-29 2014-07-02 法奈科斯公司 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR20100005476A (ko) 2008-07-07 2010-01-15 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법
WO2010006103A1 (en) 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
KR101052620B1 (ko) 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
EP2437749B8 (en) 2009-06-05 2018-02-21 Cavion, Inc. Interlaced method for treating cancer or a precancerous condition
EP2476308A2 (en) 2009-08-12 2012-07-18 Carlos Alberto Barcelo Rojas Bioelectronic system
WO2011093393A1 (ja) 2010-01-29 2011-08-04 国立大学法人岡山大学 Dravet症候群の発症可能性の判定方法およびその利用
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
KR20130139896A (ko) * 2010-09-08 2013-12-23 프로노바 바이오파마 너지 에이에스 유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
WO2012094612A1 (en) 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
JP2016506248A (ja) 2013-01-10 2016-03-03 ティーエーユー・セラピューティクス・エルエルシー 癌の処置のためのｔ型カルシウムチャネル阻害剤
US10292989B2 (en) 2014-03-28 2019-05-21 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic
JP2018520112A (ja) 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
KR101679262B1 (ko) 2015-06-08 2016-11-24 한국과학기술연구원 4-이소프로필크로만-3-올 화합물
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US9634019B1 (en) 2015-10-01 2017-04-25 Silicon Storage Technology, Inc. Non-volatile split gate memory cells with integrated high K metal gate, and method of making same
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
KR102654466B1 (ko) 2017-04-26 2024-04-08 카비온, 인코포레이티드 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법
CA3061712A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for treating dravet syndrome
GB2571978A (en) 2018-03-15 2019-09-18 Andre Fisahn Uses, compositions and methods
TW202602439A (zh) * 2018-10-03 2026-01-16 美商卡凡恩公司 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
TWI870475B (zh) 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料

Similar Documents

Publication Publication Date Title
US6458384B2 (en) Pharmaceutical with predetermined activity profile
JP6902033B2 (ja) 発作−関連障害の処置のための方法および組成物
JPH02240021A (ja) 抑うつ障害の治療用に適した制御放出製薬組成物
US9023389B1 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9034902B2 (en) Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
AU2019200479B2 (en) Melatonin mini-tablets and method of manufacturing the same
US20220168318A1 (en) Pharmaceutical compositions and methods for treatment of insomnia
CN115715769A (zh) 石杉碱的改良释放药物组合物以及其使用方法
JP2024507264A (ja) メラトニンを含む多層ペレットの製剤
AU2018282448B2 (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
US20160015698A1 (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
CN113271929A (zh) 用于帮助睡眠的组合物及方法
CN111939139A (zh) 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法
US20190151246A1 (en) Delayed-release tablets of methylphenidate
TW202017565A (zh) 用於幫助睡眠之組合物及方法
KR20180101539A (ko) 수면장애를 예방 및 치료하기 위한 약제학적 조성물